TABLE 2.
Patient demographic, clinical, and laboratory data summary
| All patients (n = 24) | High platelet function (n = 12) | Low platelet function (n = 12) | p Value | |
|---|---|---|---|---|
| Demographic data | ||||
| Age (years) | 38 (35–61) | 39 (35–52) | 37.5 (32–71) | .885 |
| % Female | 16.7 | 8.3 | 25 | .273 |
| Clinical data | ||||
| % Blunt mechanism | 87.5 | 91.7 | 83.3 | .537 |
| % Taking aspirin | 0 | 0 | 0 | .999 |
| Initial HR (bpm) | 100 (77– 109.5) | 93.5 (70.5– 106) | 100.5 (86– 121) | .272 |
| Initial SBP (mmHg) | 131.5 (120– 141) | 135 (120.5– 151.5) | 129.5 (104– 136) | .419 |
| ISS | 20 (13.5–29.5) | 13.5 (6–20) | 29.5 (21.5–34.5) | .002 |
| Crystalloid given prior to enrollment (mL) | 800 (500–1500) | 700 (150–1900) | 950 (500–1500) | .672 |
| % Transfused in first 24 h | 20.8 | 8.3 | 33.3 | .132 |
| Total in-hospital blood products received (units) | 0 (0–2.5) | 0 (0–0) | 0.5 (0–4) | .063 |
| % In-hospital mortality | 4.2 | 0 | 8.3 | .307 |
| Laboratory data | ||||
| Hemoglobin (mg/dl) | 13.45 (12.0– 14.25) | 13.7 (12.95– 14.4) | 13.2 (11.35– 13.85) | .175 |
| Platelet count (x109/L) | 208 (173– 262.5) | 208 (177.5– 264) | 201.5 (168– 262.5) | .644 |
| PT (s) | 14.45 (13.7– 16.15) | 13.0 (12.75– 13.85) | 13.45 (12.85– 14.05) | .451 |
| % PT ≥18 s | 12.5 | 0 | 25 | .064 |
| Initial [lactate] (mmol/L) | 2.4 (1.7–4.8) | 1.5 (1.2–3.25) | 3.3 (1.9–6.8) | .117 |
| Initial [ETOH] (mg/dl) | 0 (0–0) | 0 (0–0) | 0 (0–49.5) | .626 |
| Total protein (mg/dl) | 57.9 (48.4–60.2) | 58.7 (55.7–62.9) | 54.4 (36.5–59.1) | .065 |
| Aggregometry AUC–ADP (AU) | 49 (22.5–65) | 59.5 (54.5–88.5) | 22.5 (12.5–39) | .003 |
| Aggregometry AUC–AA (AU) | 34 (19–54) | 50.5 (28.5–69) | 20.5 (8–39) | .017 |
| Aggregometry AUC–TRAP (AU) | 106 (70.5–124.5) | 114.5 (94.5–139.5) | 74 (54–117.5) | .057 |
| Aggregometry AUC–collagen (AU) | 27.5 (12–53.5) | 53.5 (30.5–62) | 12 (5.5–26) | .001 |
| Aggregometry AUC–ristocetin (AU) | 28.5 (7–51) | 43 (15– 55.5) | 8.5 (3–44) | .099 |
| ROTEM–CT (s) | 60.5 (50.5–73) | 58.5 (50.5–72.5) | 64.5 (51–75) | .386 |
| ROTEM–CFT (s) | 97 (80–134) | 90 (79–110) | 99.5 (80.5–150) | .355 |
| ROTEM–alpha angle (°) | 70 (65–74) | 73 (68–74.5) | 70 (62–74) | .193 |
| ROTEM–MCF (mm) | 62 (56–65) | 62.5 (59.5–65) | 61 (51–65) | .309 |
| ROTEM–LI30 (%) | 100 (100–100) | 100 (100–100) | 100 (100–100) | .999 |
| PCF (nN) at 2 min perfusion | 86.5 (72.7–141.0) | 98.7 (82.3–145.6) | 82.9 (63.4–133.2) | .309 |
Continuous variables reported as median (IQR).
p values obtained by Wilcoxon rank-sum test for continuous variables and chi-square test for dichotomous variables.
Abbreviations: AA, arachidonic acid; ADP, adenosine diphosphate; AU, arbitrary units; AUC, area under the curve; bpm, beats per minute; CFT, clot formation time; CT, clotting time; HR, heart rate; ISS, injury severity score; LI30, lysis index after 30 min by whole blood EXTEM assay; MCF, maximum clot firmness; PCF, platelet contractile force after different durations of perfusion through previously described platelet function assay; PT, prothrombin time; ROTEM, rotational thromboelastometry whole blood EXTEM assay; SBP, systolic blood pressure; TRAP, thrombin receptor activating peptide.15